Show simple item record

dc.contributor.authorWilson, JM
dc.contributor.authorDearnaley, DP
dc.contributor.authorSyndikus, I
dc.contributor.authorKhoo, V
dc.contributor.authorBirtle, A
dc.contributor.authorBloomfield, D
dc.contributor.authorChoudhury, A
dc.contributor.authorGraham, J
dc.contributor.authorFerguson, C
dc.contributor.authorMalik, Z
dc.contributor.authorMoney-Kyrle, J
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorPanades, M
dc.contributor.authorParker, C
dc.contributor.authorRimmer, Y
dc.contributor.authorScrase, C
dc.contributor.authorStaffurth, J
dc.contributor.authorStockdale, A
dc.contributor.authorCruickshank, C
dc.contributor.authorGriffin, C
dc.contributor.authorHall, E
dc.contributor.authorCHHiP Investigators,
dc.date.accessioned2018-05-08T10:10:12Z
dc.date.issued2018-04-01
dc.identifier.citationInternational journal of radiation oncology, biology, physics, 2018, 100 (5), pp. 1179 - 1189
dc.identifier.issn0360-3016
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1670
dc.identifier.eissn1879-355X
dc.identifier.doi10.1016/j.ijrobp.2018.01.016
dc.description.abstractPURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age. METHODS AND MATERIALS: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group. RESULTS: Of 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years. CONCLUSIONS: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group.
dc.formatPrint-Electronic
dc.format.extent1179 - 1189
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCHHiP Investigators
dc.subjectIntestines
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectRadiation Injuries
dc.subjectAndrogen Antagonists
dc.subjectIncidence
dc.subjectProspective Studies
dc.subjectAge Factors
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectRadiotherapy, Intensity-Modulated
dc.subjectUrinary Bladder
dc.subjectRadiation Dose Hypofractionation
dc.titleThe Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
dc.typeJournal Article
dcterms.dateAccepted2018-01-03
rioxxterms.versionofrecord10.1016/j.ijrobp.2018.01.016
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfInternational journal of radiation oncology, biology, physics
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume100
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamICR-CTSU Urology and Head and Neck Trials Team
icr.researchteamClinical Academic Radiotherapy (Dearnaley)
dc.contributor.icrauthorDearnaley, David
dc.contributor.icrauthorCruickshank, Clare
dc.contributor.icrauthorGriffin, Clare
dc.contributor.icrauthorHall, Emma


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0